Simvastatine in the treatment of schizophrenia
Phase 3
- Conditions
- schizophrenia.schizophrenia
- Registration Number
- IRCT201410021556N65
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria:1-Diagnosis of Schizophrenia based on DSM- 5 criteria;2- Minimum Score of 20 in negative subscale of Positive and Negative Scale(PANNS) 3- Age between 18-50; 4- chronic Schizophrenia- duration of the disorder more than 2 years; ;
Exclusion Criteria
1-any other mental disorder on axis I; 2-Any serious medical or neurological problem; 3- IQ less than 70; 4- Substance dependence(except for nicotine and caffeine); 5-receiving ECT during the last 14 days,6-Depression Score less than 12 in Hamilton depression scale
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method Extrapyramidal side effects. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: by Extrapyramidal Symptoms Rating Scale.